Form D · Biotechnology
INANOVATE INC
Sioux Falls, SD · CIK 0001366325
Offering snapshot reported Jul 2, 2025 · SEC filing
- Reported sold
- $808K Offering amount: $808K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Mar 26, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 2, 2025 | Initial | $808,000 | No comparison | 2 | SEC filing |
| Nov 15, 2024 | Initial | $900,000 | No comparison | 6 | SEC filing |
| Jun 12, 2024 | Initial | $1,100,000 | No comparison | 4 | SEC filing |
| Dec 11, 2023 | Initial | $1,500,000 | No comparison | 3 | SEC filing |
| Oct 6, 2022 | Initial | $2,390,000 | No comparison | 7 | SEC filing |
| Feb 23, 2022 | Initial | $1,807,117 | No comparison | 11 | SEC filing |
| Jul 13, 2020 | Initial | $455,260 | No comparison | 6 | SEC filing |
| Nov 18, 2019 | Initial | $439,244 | No comparison | 3 | SEC filing |
| Feb 19, 2019 | Initial | $3,050,609 | No comparison | 5 | SEC filing |
| Dec 17, 2015 | Initial | $502,408 | No comparison | 5 | SEC filing |
| Jun 2, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550612
Source: Form D, filed Jul 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Arslanian | Director |
| Blaine Crissman | Director |
| Michael Goldstein | Director |
| George Holmes | Director |
| Kent Lehr | Director |
| Peter D Los | Director |
| Randall Marfin | Director |
| James E Oury | Executive |
| Katie Pohlson | Director |
| Kamran Tahamtanzade | Director |
| David Ure | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2329 N. Career Avenue Ste 113.
Sioux Falls, SD, 57107
Sioux Falls, SD, 57107